SCHEMBL6071272

SCHEMBL6071272

COC(=O)CNC(=O)c1ccc2[nH]c3c(ccc4cn[nH]c43)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.48
ALDH1A1 P00352 3/20 0.48
GAA P10253 2/20 0.48
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
MAPK1 P28482 1/20 0.39
MAOB P27338 2/20 0.39
STAMBP O95630 1/20 0.39
ITK Q08881 1/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
METTL3 Q86U44 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071757 0.93 ROCK2 (0.43) KDM4EALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL6071553 0.88 ITK (0.51) KDM4EALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL6071307 0.86 MAOB (0.41) KDM4EALDH1A1GAAMAOBHPGD
SCHEMBL6071310 0.86 ALDH1A1 (0.47) KDM4EALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL6071038 0.84 MAOB (0.39) KDM4EALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL6070577 0.81 KDM4E (0.55) KDM4EALDH1A1MAPTLMNAHTT
SCHEMBL6070463 0.81 IMPDH2 (0.54) KDM4EALDH1A1MAPTMAPK1MAOB
SCHEMBL6070498 0.81 KDM4E (0.61) KDM4EALDH1A1MAPTLMNAHTT
SCHEMBL6070912 0.80 MAPK1 (0.51) GAAMAPK1MAOBROCK2
SCHEMBL6071406 0.80 MAOB (0.48) MAPTSMN1; SMN2MAOBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US claimed
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed
EP-1599202-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-11-30 EP disclosed
WO-2004071507-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 KDM4E 1799/4885ALDH1A1 4446/4885GAA 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.